Phaseline

Companies › Initiator Pharma

Initiator Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pudafensine
TRPV1 antagonist
–Phase 2VulvodyniaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07391241PudafensinePhase 2VulvodyniaGenitourinaryDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Tioga Pharmaceuticals Azure Biotech Gesynta Pharma Suzhou Sanegene Bio R1 Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.